- Programm
- Horizon 2020 & sub-programmes
- Laufzeit
- 66 Monate (January 2018 – June 2023)
- Projektförderung
- ≈ €6 million
- Projektpartner
- 12
- Technologie-Reifegrad
- 0-2
- Projektwebsite
- Projektwebsite besuchen
Worum es geht
OSTEOproSPINE aims to improve therapeutic options for patients suffering from degenerative disc diseases by translating the patient’s peripheral blood into extra-skeletal bone. The research will be based on a therapeutic system developed in the course of the previous research project OSTEOGROW, in which an autologous carrier and a biologically active human protein were combined to accelerate and enhance bone repair. For OSTEOproSPINE, the protein was reinforced with allograft. In the course of the project, the therapy will be tested in a Phase II clinical trial in four clinical centres.
Ihre EURICE-Kontakte
Explore THE COURT
Discover THE COURT, the EURICE environment where projects, expertise and partners connect across six innovation ecosystems.
THE COURT betreten